| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8944892 | Journal of Infection and Chemotherapy | 2018 | 4 Pages |
Abstract
Take previous clinical study results together, our data suggested that L-AmB is safer agent than amphotericin B for the treatment of fungal infections in patients with eGFR<60 and hemodialysis patients at the start of treatment. Also, especially, we should use L-AmB more carefully until 9 days from the treatment started.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Hideo Kato, Mao Hagihara, Yuka Yamagishi, Yuichi Shibata, Yukiko Kato, Tatsuro Furui, Hiroki Watanabe, Nobuhiro Asai, Yusuke Koizumi, Hiroshige Mikamo,